Research programme: engineered proteins therapeutics - Cyrus Biotechnology
Alternative Names: ImmTOR-IL; ImmTOR-IL program - Cartesian TherapeuticsLatest Information Update: 22 Apr 2024
At a glance
- Originator Cyrus Biotechnology
- Developer Cartesian Therapeutics; Cyrus Biotechnology
- Class Proteins
- Mechanism of Action Interleukin 2 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Suspended Immunological disorders
Most Recent Events
- 31 Dec 2023 Cartesian Therapeutics and Cyrus Biotechnology terminates to develop engineered proteins therapeutics for Immunological disorders
- 23 Aug 2023 Research programme: engineered proteins therapeutics is available for licensing as of 17 Aug 2023
- 17 Aug 2023 Suspended - Preclinical for Immunological disorders in USA (unspecified route)